The Impact of Chronic Disease Management Program (Prolanis) to Improve The Clinical Outcome of Patients Diabetes Mellitus Type 2: A Study in Primary Health Care Center In Jakarta, Indonesia

Authors

  • Reise Manninda Fakultas Farmasi, Universitas Pancasila ,
  • Yusi Anggriani Fakultas Farmasi, Universitas Pancasila ,
  • Astrid Kartika Sari Fakultas Farmasi, Universitas Pancasila ,

DOI:

https://doi.org/10.35814/jifi.v19i2.1107

Keywords:

Clinical outcome, diabetes mellitus, primary health care center, prolanis

Abstract

Prolanis is a Chronic  Disease  Management  Program  under the Indonesian National Health Insurance for promoting and preventing chronic disease. Main activities of Prolanis program are disease control and counseling, scheduled education, scheduled exercise, participant’s remainder, and home visit. The aim of this study was to evaluate the impact of prolanis on the clinical outcome in type 2 Diabetes Mellitus (DM) patients. An observational retrospective study was evaluated for 12 months. Data was collected from medical record. 426 patients from five primary health care center in Jakarta was selected by simple random sampling and divided into prolanis and non-prolanis groups. The indicators were  the difference of clinical outcome between prolanis and non-prolanis patients was analyzed using Mann-Whitney test; the correlation of adherence with clinical outcome was analyzed using Chi-Square test.The results showed that prolanis patients had a significant improvement in Fasting Blood Glucose (FBG) compared with non-prolanis patients (P<0.05). The  adherence of prolanis patients showed a significant improvement on FBG (124 patients-58.2%). Patients with nonadherence had lower improvement on FBG, the improvement was observed only at 16 patients (7.5%) and 60 patients (28.17%) was poor FBG. Prolanis is an effective program to improve the clinical outcome of DM patients.

References

Downloads

Published

2021-10-31

Issue

Vol. 19 No. 2 (2021): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.